| __timestamp | Amicus Therapeutics, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 50829000 |
| Thursday, January 1, 2015 | 47269000 | 57305000 |
| Friday, January 1, 2016 | 71151000 | 116145000 |
| Sunday, January 1, 2017 | 88671000 | 159362000 |
| Monday, January 1, 2018 | 127200000 | 206366000 |
| Tuesday, January 1, 2019 | 169861000 | 228244000 |
| Wednesday, January 1, 2020 | 156407000 | 293355000 |
| Friday, January 1, 2021 | 192710000 | 401715000 |
| Saturday, January 1, 2022 | 213041000 | 459856000 |
| Sunday, January 1, 2023 | 275270000 | 542705000 |
| Monday, January 1, 2024 | 492128000 |
Unleashing the power of data
In the competitive landscape of biotechnology, managing operational costs is crucial for sustained growth. Over the past decade, Exelixis, Inc. and Amicus Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Exelixis, Inc. has consistently outpaced Amicus Therapeutics, Inc. in SG&A spending, with a notable increase of approximately 967% from 2014 to 2023. In contrast, Amicus Therapeutics, Inc. saw a rise of about 1,229% over the same period. This divergence highlights Exelixis's aggressive expansion strategy, while Amicus's growth reflects a more measured approach. By 2023, Exelixis's SG&A expenses were nearly double those of Amicus, underscoring its commitment to scaling operations. These trends offer a window into the strategic priorities of these biotech firms, providing valuable insights for investors and industry analysts alike.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Merus N.V.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and HUTCHMED (China) Limited
Comparing SG&A Expenses: Exelixis, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of MorphoSys AG and Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.